Evusheld (tixagevimab/cilgavimab), isolated from COVID-19 patients, can bind to different locations of the receptor-binding region of the SARS-CoV-2 S protein to neutralize SARS-CoV-2 [56,57]. The gene discussed is PROS1; the disease is COVID-19.